About ARDAT
ARDAT is a new consortium of 32 international partners from academia, industry, and small/medium enterprises whose aim is to develop and provide tools that will advance our knowledge in the field of viral gene/cell therapy and so accelerate the development of new treatments for rare diseases.
New model systems
Developing improved and sustainable model systems for predicting product safety
Therapy improvement
Enhancing gene therapy vectors for better immune evasion and stability
Regulatory engagement
Establishing a comprehensive database on safety and efficacy of advanced therapies
Project structure
ARDAT
Accelerating Research & Development for Advanced Therapies
Work package 1
Project management to specify processes and principles
Work package 2
Standardized models for predicting product immunogenicity
Work package 3
Understanding of gene/cell therapy drug metabolism
Work package 4
Clinical factors around pre-existing immunity
Principal project objectives
Pre-clinical studies
Developing standardized models for predicting immunogenicity
Vector enhancement
Understanding gene/cell therapy drug molecular stability and metabolism
Clinical research
Investigating clinical factors around pre-existing immunity
Data Processing & Analysis
Establish a comprehensive and sustainable database on safety and efficacy of advanced therapies
Project structure
Work package 1
Project management to specify processes and principles
Work package 2
Standardized models for predicting product immunogenicity
Work package 3
Understanding of gene/cell therapy drug metabolism
Work package 4
Clinical factors around pre-existing immunity
Work package 5
Engagement with regulators and database development
ARDAT
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 945473. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA [Pfizer and Bayer] .
Any information on this website solely reflects the author’s view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.
